Bayer was invited to submit evidence for this single technology appraisal for regorafenib in May 2013. The appraisal was suspended shortly afterwards because the company explained that there was no evidence base on which to compare regorafenib for metastatic colorectal cancer with standard care in the UK. However, the company expected that an ongoing trial would provide these data, and that the trial was expected to complete in 2014.
The company has now reviewed the baseline characteristics of the people recruited to that trial. It considered that the number of people in the trial who have had care equivalent to standard care in the UK is too small to form the basis of a submission for this appraisal.
NICE has therefore terminated this single technology appraisal.